Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment' returned 32 results - Page 1 of 2   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017   GlobalData, Dec 2010, Pages: 50 “Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017” is an essential source of information and analysis on the global ADHD Disease and Therapy Review: Attention Deficit Hyperactivity Disorder (ADHD)   Timely Data Resources, Inc., Feb 2011, Pages: 11 Sales information for key pharmaceuticals VII. COMMENTS VIII. REFERENCES/RESOURCES Disease and Therapy Review: Attention Deficit Hyperactivity Disorder (ADHD) Specialty Pharmaceutical Industry - 2011 Yearbook   GBI Research, May 2011, Pages: 168 Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Treatment Seeking Population, 2001–2017 47 Figure 23: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global Attention Deficit Hyperactivity Disorder (ADHD)   Apollo Managed Care Consultants, June 2011, Pages: 70 Attention deficit hyperactivity disorder or ADHD is a condition that makes it difficult for children to control their behavior in home, school and social settings. It is one of the most common ADHD Therapeutics - Global Strategic Business Report   Global Industry Analysts, Inc., June 2010, Pages: 321 - AN INSIGHT II-11 Attention Deficit Hyperactivity Disorder (ADHD) - Introduction II-11 Brief History of the Disorder Royalty Rates for Pharmaceuticals & Biotechnology, 7th Edition   Intellectual Property Research Associates IPRA, Sep 2010, Pages: 360 Arthritis Drug Humira - Asthma Drug – Oral Administration - Asthma Drug – Oral Administration - Attention Deficit Hyperactivity Disorder Therapy - Attention Deficit Hyperactivity Disorder - Attention Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010   GBI Research, Nov 2011, Pages: 230 sclerosis, Parkinson’s disease, diabetic neuropathy, major depressive disorder (MDD), bipolar disorder, schizophrenia insomnia, epilepsy, attention deficit hyperactivity disorder (ADHD) and migraine The Science of ADHD: A Guide for Parents and Professionals   John Wiley and Sons Ltd, Oct 2010, Pages: 352 The Science of ADHD addresses the scientific status of Attention-Deficit Hyperactivity Disorder in an informed and accessible way, without recourse to emotional or biased viewpoints. The author DSM-IV-TR in Action, 2nd Edition   John Wiley and Sons Ltd, Sep 2010, Pages: 551 and Shirley-Ann Amos). Overview of Disruptive Behavior Disorders. Children are not little adults. Childhood and Adolescent Disorders: Assessing Mental Health Factors. Attention Deficit Hyperactivity Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018   GlobalData, Nov 2011, Pages: 102 Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Summary GlobalData, the industry analysis specialist, has released its new report CNS Drug Discoveries: Attention Deficit Hyperactivity Disorder Chapter   Espicom Business Intelligence Ltd, Nov 2006, Pages: 84 on the full report please search our Website. This chapter is available for purchase separately. ATTENTION DEFICIT HYPERACTIVITY DISORDER EXECUTIVE SUMMARY THE FACTS PATIENT STATISTICS PATIENT MODEL DRUG Opportunities and Challenges in the Adult Attention-Deficit/Hyperactivity Disorder Market November 14, 2005   Decision Resources, Inc., Nov 2005, Pages: 18 -Deficit/Hyperactivity Disorder, 2005 Table 4. Pharmacological Therapies in Development for Treatment of Attention-Deficit/ Hyperactivity Disorder, 2005 Figure 1. Total Prevalent, Diagnosed, and Drug The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis   GBI Research, Dec 2009, Pages: 198 Disorder, Epilepsy, Major depressive disorder (MDD), anxiety and panic disorder, Attention Deficit Hyperactivity Disorder (ADHD) and Insomnia. - Analysis of the CNS diseases therapeutics DNA Sequencing - Technologies, Markets and Companies   Jain PharmaBiotech, Feb 2012, Pages: 299 -deficit/hyperactivity disorder Sequencing genomes of microbes DNA sequencing for study of bacterial epidemics Human Microbiome Project Pyrosequencing of microbial flora in leg ulcers Sequencing of gut Learning and Attention Disorders in Adolescence and Adulthood: Assessment and Treatment, 2nd Edition   John Wiley and Sons Ltd, April 2011, Pages: 636 regarding Learning Disabilities (LD) and Attention-Deficit/Hyperactivity Disorder (ADHD), this Second Edition of Learning and Attention Disorders in Adolescence and Adulthood provides practitioners Attention Deficit Disorder: Practical Coping Mechanisms, Second Edition   Informa Healthcare, Dec 2006, Pages: 408 , novel treatment approaches, including a new cognitive training program, methods to diagnosis ADD/ADHD and separate it from other overlapping disorders, and mis-diagnosis. What is ADHD? Problem of Over U.S. Attention Deficit Hyperactivity Disorder (ADHD) Markets   Frost & Sullivan, May 2003 New Non-stimulants Attract Broader User Base The non-addictive properties of new non-stimulants have given an impetus to the market for attention deficit hyperactivity disorder (ADHD) medication Managing Behavioral Healthcare, 3rd Edition 2011 Update   Apollo Managed Care Consultants, Feb 2011, Pages: 440 defiant disorder, Attention Deficit/Hyperactivity Disorders; Cognitive/Mental disorders d/t general medical condition, children, adolescents; Web resources. - Utilization management – Behavioral Health Biomarkers - Technologies, Markets and Companies   Jain PharmaBiotech, Feb 2012, Pages: 864 Attention-deficit hyperactivity disorder Biomarkers for autism Biomarkers of depression Biomarkers of psychosis Biomarkers of schizophrenia Biomarkers of abnormalities of visual information processing Attention Deficit Hyperactivity Disorder: Concepts, Controversies, New Directions   Informa Healthcare, Nov 2007, Pages: 448 Conference. RESOURCES Attention Deficit Hyperactivity Disorder: Concepts, Controversies, New Directions Results:  First -   Prev -   1 -   2 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets3    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network